Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Ocean on Impact of the PRODIGE 24/CCTG PA.6 Trial in Pancreatic Cancer

December 3rd 2019

Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.

Dr. Benson on the Ongoing Research With Immunotherapy in mCRC

December 3rd 2019

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Genomic Era Trials Drive Discovery

December 2nd 2019

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Evolving HCC Treatment Paradigm: Combinations and Sequencing

December 2nd 2019

Advanced HCC: Guiding Second-Line Therapy With AFP

December 2nd 2019

Second-Line Use of I/O Therapy for Advanced HCC

December 2nd 2019

Second-Line Therapy for Advanced HCC: The CELESTIAL Trial

December 2nd 2019

Second-Line Therapy for Advanced HCC: The RESOURCE Trial

December 2nd 2019

Future of Frontline Combination Therapy in Advanced HCC

December 2nd 2019

Advanced HCC: Trial Data for Frontline Combination Therapy

December 2nd 2019

Frontline I/O Therapy for HCC: Results From CheckMate459

December 2nd 2019

Selecting a Frontline TKI for Advanced HCC

December 2nd 2019

Newly Diagnosed Advanced HCC: Frontline Therapy Overview

December 2nd 2019

ASTRO Presents First Guideline for RT in Pancreatic Cancer

November 30th 2019

Recent strides in systemic treatment approaches and the broader application of stereotactic radiation led the American Society for Radiation Oncology to issue its first guideline regarding radiation therapy in patients with pancreatic cancer.

Dr. Patel on Sequencing Therapy in Rectal Cancer

November 28th 2019

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

FDA Grants Priority Review to Pemigatinib for FGFR2+ Cholangiocarcinoma

November 27th 2019

The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

Dr. Rajdev on the Use of Somatostatin Analogs in Neuroendocrine Tumors

November 23rd 2019

Lakshmi N. Rajdev, MD, discusses the use of somatostatin analogs in patients with neuroendocrine tumors.

Atezolizumab Plus Bevacizumab Extends Survival in Frontline HCC

November 23rd 2019

The frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) reduced the risk of disease progression or death by 42% compared with sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma.

Dr. Kaubisch on the REACH Trials in HCC

November 21st 2019

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.

Dr. Ocean Discusses the Use of ctDNA in Pancreatic Cancer

November 20th 2019

Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.